Mineralys Therapeutics (Mineralys Therapeutics) Net Income : $-90.80 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mineralys Therapeutics Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Mineralys Therapeutics's Net Income for the three months ended in Mar. 2024 was $-31.51 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-90.80 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Mineralys Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.70.

Mineralys Therapeutics Net Income Historical Data

The historical data trend for Mineralys Therapeutics's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mineralys Therapeutics Net Income Chart

Mineralys Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Income

-3.43

-19.41

-29.80

-71.90

Mineralys Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income	Get a 7-Day Free Trial							-12.61	-12.14	-22.76	-24.39	-31.51

Mineralys Therapeutics Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Mineralys Therapeutics's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

	Net Income		(A: Dec. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-71.898	+	0	+	0	+	0
=	-71.90

Mineralys Therapeutics's Net Income for the quarter that ended in Mar. 2024 is calculated as

	Net Income		(Q: Mar. 2024 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-31.508	+	0	+	0	+	0
=	-31.51

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-90.80 Mil.

Mineralys Therapeutics (NAS:MLYS) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Mineralys Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

Earnings per Share (Diluted) (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-31.508	-	0)	/	44.901
	=	-0.70

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Mineralys Therapeutics Net Income Related Terms

Thank you for viewing the detailed overview of Mineralys Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Mineralys Therapeutics (Mineralys Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mineralys Therapeutics Inc (NAS:MLYS) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087

Website

https://mineralystx.com

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Executives

Jon Congleton	director, officer: Chief Executive Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Glenn Sblendorio	director	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
David Malcom Rodman	officer: Chief Medical Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Srinivas Akkaraju	director, 10 percent owner	565 EVERETT AVENUE, PALO ALTO CA 94301
Hbm Healthcare Investments (cayman) Ltd.	10 percent owner	GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,, PO BOX 30852, GRAND CAYMAN E9 KY1-1204
Adam Scott Levy	officer: CFO, Chief Bus. Off. and Secy.	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
Catalys Pacific Fund, Lp	10 percent owner	301 9-19 HACHIYAMA, SHIBUYA, TOKYO M0 150-0035
Olivier Litzka	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Takeshi Takahashi	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Brian Taylor Slingsby	director, 10 percent owner	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Ra Capital Nexus Fund Iii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Samsara Biocapital, L.p.	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Alexander Asam	director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361